Updated Australian Guidelines for Mild Asthma: What's Changed and Why?

Overview

Journal Aust Prescr

Date 2020 Dec 28

PMID 33363311

Citations 2

Authors

Helen K Reddel

Affiliations

Soon will be listed here.

Abstract

The Australian asthma guidelines have recently been updated and include additional treatment options for adults and adolescents with mild asthma Mild asthma is not necessarily a benign condition and patients are still at risk of severe flare-ups, particularly if they overuse short-acting beta2 agonists such as a salbutamol inhaler For adults and adolescents with mild asthma, the updated guidelines include as-needed inhaled low-dose budesonide–formoterol as an alternative to daily low-dose inhaled corticosteroid plus as-needed short-acting beta2 agonist The budesonide–formoterol combination should be taken as needed to provide symptom relief and reduce the risk of severe exacerbations

Citing Articles

Over-the-counter use of short-acting beta-2 agonists: a systematic review.

Loh Z, Hussain R, Ong S, Saini B, Muneswarao J, Ur-Rehman A J Pharm Policy Pract. 2023; 16(1):119.

PMID: 37814312 PMC: 10561505. DOI: 10.1186/s40545-023-00627-z.

How to step down asthma preventer treatment in patients with well-controlled asthma - more is not always better.

Reddel H, Foxley G, Davis S Aust Prescr. 2022; 45(4):125-129.

PMID: 36110163 PMC: 9427634. DOI: 10.18773/austprescr.2022.033.

References

Sobieraj D, Weeda E, Nguyen E, Coleman C, White C, Lazarus S . Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018; 319(14):1485-1496. PMC: 5876810. DOI: 10.1001/jama.2018.2769. View

Buhl R, Kuna P, Peters M, Andersson T, Naya I, Peterson S . The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard.... Respir Res. 2012; 13:59. PMC: 3561645. DOI: 10.1186/1465-9921-13-59. View

Hatter L, Bruce P, Braithwaite I, Holliday M, Fingleton J, Weatherall M . ICS-formoterol reliever ICS and short-acting β-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021; 7(1). PMC: 7836558. DOI: 10.1183/23120541.00701-2020. View

Price D, Trudo F, Voorham J, Xu X, Kerkhof M, Jie J . Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018; 11:193-204. PMC: 6121746. DOI: 10.2147/JAA.S176026. View

Reddel H, FitzGerald J, Bateman E, Bacharier L, Becker A, Brusselle G . GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019; 53(6). DOI: 10.1183/13993003.01046-2019. View

Beasley R, Holliday M, Reddel H, Braithwaite I, Ebmeier S, Hancox R . Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. N Engl J Med. 2019; 380(21):2020-2030. DOI: 10.1056/NEJMoa1901963. View

Nwaru B, Ekstrom M, Hasvold P, Wiklund F, Telg G, Janson C . Overuse of short-acting β-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020; 55(4). PMC: 7160635. DOI: 10.1183/13993003.01872-2019. View

OByrne P, FitzGerald J, Bateman E, Barnes P, Zheng J, Gustafson P . Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2020; 9(2):149-158. DOI: 10.1016/S2213-2600(20)30416-1. View

Hardy J, Baggott C, Fingleton J, Reddel H, Hancox R, Harwood M . Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019; 394(10202):919-928. DOI: 10.1016/S0140-6736(19)31948-8. View

10.

Stanford R, Shah M, DSouza A, Dhamane A, Schatz M . Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012; 109(6):403-7. DOI: 10.1016/j.anai.2012.08.014. View

11.

Bateman E, Reddel H, OByrne P, Barnes P, Zhong N, Keen C . As-Needed Budesonide-Formoterol versus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018; 378(20):1877-1887. DOI: 10.1056/NEJMoa1715275. View

12.

OByrne P, FitzGerald J, Bateman E, Barnes P, Zhong N, Keen C . Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018; 378(20):1865-1876. DOI: 10.1056/NEJMoa1715274. View

13.

Reddel H, Lembke K, Zwar N . The cost of asthma medicines. Aust Prescr. 2018; 41(2):34-36. PMC: 5895474. DOI: 10.18773/austprescr.2018.011. View

14.

Dusser D, Montani D, Chanez P, de Blic J, Delacourt C, Deschildre A . Mild asthma: an expert review on epidemiology, clinical characteristics and treatment recommendations. Allergy. 2007; 62(6):591-604. DOI: 10.1111/j.1398-9995.2007.01394.x. View

15.

Reddel H, Ampon R, Sawyer S, Peters M . Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017; 7(9):e016688. PMC: 5623555. DOI: 10.1136/bmjopen-2017-016688. View

16.

Lazarinis N, Jorgensen L, Ekstrom T, Bjermer L, Dahlen B, Pullerits T . Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2013; 69(2):130-6. PMC: 3913208. DOI: 10.1136/thoraxjnl-2013-203557. View

17.

Engelkes M, Janssens H, de Jongste J, Sturkenboom M, Verhamme K . Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2014; 45(2):396-407. DOI: 10.1183/09031936.00075614. View